{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-037634","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.760430+00:00","generated_at":"2026-05-24T22:16:34.381127+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Atossa to pursue metastatic breast cancer indication; (Z)-endoxifen more than doubled PFS vs tamoxifen (7.2 vs 2.4 mo)","bullets":["Strategic decision to pursue metastatic breast cancer indication for (Z)-endoxifen, citing potentially faster regulatory path.","Median PFS more than doubled to 7.2 months vs 2.4 months for tamoxifen in CDK4/6i-naïve patients.","Also engaging FDA on additional indications: breast cancer prevention and neoadjuvant therapy.","Early data show Ki-67 ≤10% response rate above 85% across doses in neoadjuvant setting."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-037634","json":"https://secwatch.observer/filing/0000950170-25-037634.json","markdown":"https://secwatch.observer/filing/0000950170-25-037634.md","text":"https://secwatch.observer/filing/0000950170-25-037634.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000095017025037634/0000950170-25-037634-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000095017025037634/atos-20250311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T22:16:34.381127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}